Welcome to our dedicated page for Oruka Therapeutics SEC filings (Ticker: ORKA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oruka Therapeutics, Inc. (NASDAQ: ORKA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, financial statements, and material agreements. As a Nasdaq-listed clinical-stage biotechnology company focused on biologic therapies for chronic skin diseases, Oruka uses its SEC filings to report key corporate, financial, and governance information related to its psoriasis and inflammatory disease programs.
Investors can review Form 8-K current reports where Oruka describes material events such as private placement financings, changes in directors and executive officers, and the terms of securities purchase agreements and registration rights agreements. These filings also document board appointments, committee roles, director compensation, and equity awards, providing detail on corporate governance and leadership transitions.
Periodic reports such as Form 10-Q and Form 10-K (when available) contain condensed consolidated financial statements, including research and development and general and administrative expenses, net losses, cash, cash equivalents, and marketable securities. For a clinical-stage company like Oruka, these filings help readers understand the level of investment in plaque psoriasis and other dermatologic programs, as well as the company’s capital position and runway assumptions.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points, such as trial-related disclosures, financing structures, and changes in share count. Users can also access information related to equity issuances and warrant terms, and track how Oruka’s capital structure evolves over time. Real-time updates from EDGAR ensure that new ORKA filings, including any future proxy statements or insider transaction reports on Form 4, appear promptly with plain-language explanations to support more efficient review.
Oruka Therapeutics, Inc. filed a shelf registration to offer up to $1,000,000,000 of common stock, preferred stock, depositary shares and warrants, to be sold from time to time in one or more offerings. The prospectus states securities may be sold directly, through agents or underwriters, on a continuous or delayed basis, with specific terms provided in prospectus supplements. The company’s common stock trades on the Nasdaq Global Market under the symbol ORKA, with a reported last sale price of $50.43 per share on April 1, 2026. The prospectus incorporates by reference the company’s periodic reports and risk factors, and notes that use of proceeds, pricing, and underwriting terms will be set forth in future prospectus supplements.
Oruka Therapeutics Inc: The Vanguard Group filed an amendment to its Schedule 13G reporting that it holds 0 shares of Oruka Therapeutics Inc common stock, representing 0% of the class following an internal realignment. The filing states Vanguard disaggregated certain subsidiaries’ holdings as of January 12, 2026 and that those subsidiaries will report separately. The amendment is signed by Ashley Grim on March 27, 2026.
Oruka Therapeutics, Inc. Chief Executive Officer Lawrence Otto Klein reported an open-market sale of 1,729 shares of common stock at $41.30 per share. According to the filing, this sale was executed automatically under the company’s non-discretionary sell-to-cover procedure to satisfy tax withholding tied to vested restricted stock units. After this transaction, Klein directly holds 927,309 shares of Oruka Therapeutics common stock, indicating he retains a substantial equity position following the tax-related sale.
Oruka Therapeutics, Inc. senior vice president of finance Arjun Agarwal reported an automatic sale of common stock tied to tax withholding on vested restricted stock units. A total of 395 shares were sold on March 16, 2026 at $41.30 per share under the company’s non-discretionary sell-to-cover procedure. After this tax-related transaction, Agarwal directly holds 18,863 shares of Oruka common stock.
Oruka Therapeutics, Inc. Chief Operating Officer Laura Lee Sandler reported an automatic sale of 600 shares of common stock at $41.30 per share. The footnote explains that these sales were made under the company’s automatic, non-discretionary sell-to-cover procedure to satisfy tax withholding obligations from vesting restricted stock units. After this tax-related sale, Sandler directly holds 236,984 shares of Oruka common stock.
Oruka Therapeutics Chief Medical Officer Joana Goncalves exercised equity awards and sold shares in a pre-planned, tax-related transaction. She exercised employee stock options and an employee warrant covering a total of 7,000 shares of common stock at exercise prices of $6.84 and $7.80 per share.
On the same date, she sold 7,641 shares of common stock in multiple open-market transactions at weighted average prices between approximately $39.65 and $42.28. The filing states these sales were made under a Rule 10b5-1 trading plan and Oruka’s automatic, non-discretionary sell-to-cover procedure for tax withholding. Following the transactions, she directly holds 33,377 common shares.
Oruka Therapeutics General Counsel Paul T. Quinlan reported a small, tax-related share sale. On the vesting of restricted stock units, 733 shares of common stock were automatically sold at $41.30 per share under the company’s non-discretionary sell-to-cover procedure to satisfy tax withholding. After this transaction, he directly holds 31,767 shares.
Oruka Therapeutics, Inc. files its annual report describing a major transformation into a clinical-stage dermatology-focused biopharma following its August 2024 merger with Pre‑Merger Oruka and name change from ARCA biopharma. The company now centers on monoclonal antibodies for psoriasis and other inflammatory diseases.
Lead candidate ORKA‑001, an extended half-life IL‑23p19 antibody, is in Phase 2a and 2b psoriasis trials (EVERLAST‑A and EVERLAST‑B) after Phase 1 data showed an approximately 100‑day half‑life and favorable safety. Co‑lead ORKA‑002, a long‑acting IL‑17A/F antibody, showed a 75–80 day half‑life in Phase 1 and has entered a Phase 2 psoriasis study (ORCA‑SURGE), with HS and broader I&I indications planned. Oruka holds exclusive global rights to ORKA‑001 and ORKA‑002 via royalty‑bearing licenses from Paragon and uses WuXi Biologics’ cell line technology for manufacturing.
Oruka Therapeutics, Inc. Chief Operating Officer Laura Lee Sandler reported a combination of option exercise and share sales. She exercised an employee warrant for 5,000 shares of common stock at $7.80 per share and received common stock.
On the same date, she sold 5,000 shares of common stock in open-market transactions, including 2,325 shares at a weighted average price of $33.2843 and 2,675 shares at a weighted average price of $33.8077. The sales were made under a pre-arranged Rule 10b5-1 trading plan. After these transactions, she directly owned 237,584 shares of Oruka Therapeutics common stock.
Oruka Therapeutics Chief Medical Officer Joana Goncalves reported option exercises and stock sales in Common Stock of Oruka Therapeutics, Inc. On February 17, 2026, she exercised an Employee Stock Option for 3,500 shares at $6.84 and an Employee Warrant for 3,500 shares at $7.80, acquiring Common Stock through derivative conversion.
On the same date, she conducted open-market sales of 6,064 shares at a weighted average price of $32.3009 and 936 shares at a weighted average price of $32.7842, under a Rule 10b5-1 trading plan entered into on September 19, 2025. After these transactions, she directly owned 34,018 shares of Common Stock, plus 218,063 employee stock options and 189,492 employee warrants outstanding.